Navigation Links
Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provid's Unique MS Drug Candidate
Date:11/17/2010

NEW YORK and NORTH BRUNSWICK, N.J., Nov. 17, 2010 /PRNewswire/ -- Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced an expansion of their partnership to support Provid's preclinical studies of their candidate MS drug, PV-267.  This novel, highly selective small molecule is designed to block a critical step in the autoimmune process of MS, which leads to the destruction of the body's protective myelin in the central nervous system and to the ultimate accumulation of disability.  

The expanded partnership will enable Provid to enhance knowledge of the immune mechanisms involved in the activity of PV-267, paving the way for future development and clinical studies.  The biological studies will be carried out by Dr. Thomas Forsthuber, Provid's collaborator and a leading immunologist at the University of Texas San Antonio.  

"The partnership between Fast Forward and Provid was begun in May 2009 and helped fund important research," noted Dr. Gary Olson, Provid's President and CEO.  "In these studies, PV-267 was shown to be active in an animal model of MS in transgenic mice that carry the human gene for HLA-DR2, a disease-associated molecule that is involved in the attack of the immune system on myelin, the insulating protein on nerves that are damaged in MS."  Dr. Olson added, "DR2 is present in about 60% of the MS population and PV-267 was designed to be a potent and selective blocker of DR2.  This specificity suggests that PV-267 could have a better safety profile compared with immune-modifying therapies since it will not affect other, normal immune responses."  

The partnership with Provid is one of a series of partnerships between Fast Forward and early stage biotechnology companies. "The results of our initial funding of the PV-267 project are very encouraging, which prompts us to extend our partnership with Provid to continue development of this promising new approach to treating MS," said Dr. Timothy Coetzee, Fast Forward's President.  

The National Multiple Sclerosis Society funds research in a wide range of scientific areas including immune mechanisms, genetics, nerve regeneration, and symptom managements.  The agreement with Provid is a part of the Society's Fast Forward initiative through which Fast Forward will partner with early stage biotechnology and pharmaceutical companies to develop treatments, diagnostics, medical devices, and related technologies to treat, reverse, and ultimately cure MS.  Under terms of the agreement, Fast Forward will provide Provid with funds to support pre-clinical studies with PV-267.  In addition, Fast Forward will receive warrants for purchase of shares in the company.

About Fast Forward, LLCFast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS.  Fast Forward will accomplish its mission by connecting university-based MS research with private-sector drug development and by funding small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS.  www.fastforward.org

About the National Multiple Sclerosis SocietyMS is a chronic, unpredictable neurological disease that affects the central nervous system. It is thought to be an autoimmune disorder, meaning the immune system incorrectly attacks healthy tissue. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. These problems may be permanent or may come and go. The National MS Society addresses the challenges of each person affected by MS by funding cutting-edge research, driving change through advocacy, facilitating professional education, collaborating with MS organizations around the world, and providing programs and services designed to help people with MS and their families move their lives forward. The Society is comprised of people who want to do something about MS now, and is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.

About Provid Provid Pharmaceuticals Inc. is a drug discovery company that has expertise in the design and optimization of drug candidates for biological targets, using concepts of structure-aided design, medicinal chemistry, and peptide mimetics technology.  The company has applied this capability to internal programs in autoimmune disease and oncology.  In addition, Provid supplies expert medicinal chemistry services to the biotech and pharmaceutical industries to translate early biological discoveries into commercial opportunities.

Contacts:Fast Forward, LLCArney Rosenblat

Tel: (212) 476-0436

Email: arney.rosenblat@nmss.orgProvid Pharmaceuticals, Inc.Dr. Gary Olson

Tel: 732-565-1101 x626

Email: gary.olson@providpharma.com

www.providpharma.com
'/>"/>

SOURCE Provid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Raptor Pharmaceuticals Provides Update of Product Programs
7. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
8. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
9. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
10. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... and Markets has announced the addition of the "Dry eye Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... following questions: What are the key drugs ... in the Global Dry eye market? What are the ...
(Date:2/24/2017)... CHAPEL HILL, N.C. , Feb. 24, 2017 ... sector are exploring ways to increase their self-service ... as Health Care Providers (HCPs). New ... that many pharma organizations have developed self-service website ... questions electronically.  This is just one of many ...
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Smart Machine ... from Oxford University predict that 47 percent of all jobs in the United States ... “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ... have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual ... X. , With ProGlass Prism users are given the tools and effects to ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
Breaking Medicine News(10 mins):